SEC Comment Letter 0000000000-25-003258 to Vor Biopharma Inc. (VOR)
Vor Biopharma Inc.
Date: March 26, 2025 · CIK: 0001817229 · Accession: 0000000000-25-003258
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285969
Letter
Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285969 Dear Robert Ang:
March 26, 2025
Robert Ang Chief Executive Officer Vor Biopharma Inc. 100 Cambridgepark Drive Suite 101 Cambridge, MA 02140
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Katie Kazem
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 26, 2025 Robert Ang Chief Executive Officer Vor Biopharma Inc. 100 Cambridgepark Drive Suite 101 Cambridge, MA 02140 Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285969 Dear Robert Ang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Katie Kazem </TEXT> </DOCUMENT>